-

Availability of Transgene’s 2022 Universal Registration Document

STRASBOURG, France--(BUSINESS WIRE)--TRANSGENE (Paris: TNG) today announced that its Universal registration document for fiscal year ended December 31, 2022, was submitted to the French stock market authority (Autorité des Marchés financiers – AMF) in ESEF format and registered under the reference D.23-0237.

The 2022 Universal Registration Document is available to the public under the conditions provided by applicable regulations. The document is available on the Company’s website: www.transgene.fr, in the “Investors/Financial information” section and on the AMF website: www.amf-france.org.

It includes:

- the 2022 annual financial report;

- the report of the Board of Directors on corporate governance;

- the statutory auditor’s reports;

- information on the share buyback program;

- information related on the auditor’s fees.

The universal registration document also includes information on the Company’s environmental and social responsibility.

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Transgene

BOURSE:TNG

Release Versions
$Cashtags

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

More News From Transgene

Transgene Announces Upcoming Investor Meetings

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below. Transgene will meet institutional investors at the 13th Annual LifeSci Advisors Corporate Access Event in San Francisco from January 8 to 10, 2024, in conjunction with the J.P. Morgan Healthcare conference. The Company will also attend: 27th ODDO BHF Forum (virtual): January 15-16, 2024; Invest...

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of it...

Transgene Reports Business Update and Q3 2023 Financial Position

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its financial position for the quarter ending September 30, 2023. During the third quarter of 2023, Transgene’s clinical-stage immunotherapy portfolio continued to advance. Notable progress included the treatment of the first patient in the Part B of Phase I trial assess...
Back to Newsroom